Bcl-xL overexpression and its association with the progress of tongue carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 11, 2014, Pages 7360-7377

  Zhang, Kailiang ^a   Jiao, Kangli ^a   Xing, Zhankui ^a   Zhang, Li ^a   Yang, Juan ^b   Xie, Xiaodong ^a   Yang, Lan ^a  

^a LANZHOU UNIVERSITY   (China)

^b First Hospital of Chinese People's Liberation Army   (China)

Author keywords

Bcl xL; Immunohistochemistry; Real time polymerase chain reaction; Tongue carcinoma tissues; Western blot

Indexed keywords

BCL2L1 PROTEIN, HUMAN; PROTEIN BCL X; TUMOR MARKER;

ADENOCARCINOMA; APOPTOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; BCL-X PROTEIN; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TONGUE NEOPLASMS;

EID: 84920129462     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Annertz K, Anderson H, Biörklund A, Möller T, Kantola S, Mork J, Olsen JH, Wennerberg J. Incidence and survival of squamous cell carcinoma of the tongue in scandinavia, with special reference to young adults. Int J Cancer 2002; 101: 95-99.
2. Brown LM, Check DP, Devesa SS. Oral cavity and pharynx cancer incidence trends by subsite in the united states: Changing gender patterns. J Oncol 2012; 2012: 649498.
3. Hilly O, Shkedy Y, Hod R, Soudry E, Mizrachi A, Hamzany Y, Bachar G, Shpitzer T. Carcinoma of the oral tongue in patients younger than 30 years: Comparison with patients older than 60 years. Oral Oncol 2013; 49: 987-990.
4. Li R, Koch WM, Fakhry C, Gourin CG. Distinct epidemiologic characteristics of oral tongue cancer patients. Otolaryngol Head Neck Surg 2013; 148: 792-796.
5. Patel SC, Carpenter WR, Tyree S, Couch ME, Weissler M, Hackman T, Hayes DN, Shores C, Chera BS. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol 2011; 29: 1488-1494.
6. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-1254.
7. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
8. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol 1997; 6: 133-142.
9. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
10. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nuñez G, Castle VP. Bcl-xl is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576-2582.
11. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G. Bcl-2 and bcl-xl antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62-67.
12. Chao DT, Korsmeyer SJ. Bcl-2 family: Regulators of cell death. Ann Revi Immunol 1998; 16: 395-419.
13. Zangemeister-Wittke U, Leech SH, Olie RA, Simões-Wüst AP, Gautschi O, Luedke GH, Natt F, Häner R, Martin P, Hall J. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xl expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6: 2547-2555.
14. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the bcl-2 family. J Cell science 2009; 122: 437-441.
15. Zhou F, Yang Y, Xing D. Bcl-2 and bcl-xl play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011; 278: 403-413.
16. Percicote AP, Leme FEG, Almeida TVR, Freitas AKE, Gugelmin ES, Noronha Ld. Immunohistochemical expression of p53, bcl-2, bax and vegfr1 proteins in nephroblastomas. Jornal Brasileiro de Patologia e Medicina Laboratorial 2013; 49: 50-56.
17. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
18. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-620.
19. Cory S, Huang DC, Adams JM. The bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-8607.
20. Coultas L, Strasser A. The role of the bcl-2 protein family in cancer. Semin Cancer Biol 2003; 13: 115-123.
21. Kirkin V, Joos S, Zörnig M. The role of bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249.
22. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y. Bax and bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124: 503-510.
23. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899-1911.
24. Cleland MM, Norris KL, Karbowski M, Wang C, Suen DF, Jiao S, George NM, Luo X, Li Z, Youle RJ. Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ 2010; 18: 235-247.
25. Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol 2012; 7: 124.
26. Adams J, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
27. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The bcl-2 family reunion. Molecular Cell 2010; 37: 299-310.
28. Rahman M. Bcl-2 family proteins: Insight role of mitochondrial apoptosis pathway in cancer cells. Novel Science Int J Pharmaceutical Sciences 2013; 1.
29. Park D, Magis AT, Li R, Owonikoko TK, Sica GL, Sun SY, Ramalingam SS, Khuri FR, Curran WJ, Deng X. Novel small-molecule inhibitors of bcl-xl to treat lung cancer. Cancer Res 2013; 73: 5485-5496.
30. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
31. Gao Q, Yang S, Kang MQ. Influence of survivin and bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Rep 2012; 5: 1409-1414.
32. Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, Ding YG, Wan XB, Guan Z, Li HG. Low expression of beclin 1, associated with high bcl-xl, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy 2012; 8: 389-400.
33. Simões-Wüst AP, Olie RA, Gautschi O, Leech SH, Häner R, Hall J, Fabbro D, Stahel RA, Zangemeister-Wittke U. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells. Int J Cancer 2000; 87: 582-590.
34. Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Bri J Cancer 2005; 92: 2185-2189.
35. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96: 287-295.
36. Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M. Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 2002; 56: 43-49.
37. Lee JU, Hosotani R, Wada M, Doi R, Kosiba T, Fujimoto K, Miyamoto Y, Tsuji S, Nakajima S, Nishimura Y. Role of bcl-2 family proteins (bax, bcl-2 and bcl-x) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999; 35: 1374-1380.
38. Miyamoto Y, Hosotani R, Wada M, Lee JU, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Kato M, Shimada Y. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in pancreatic cancers. Oncology 1999; 56: 73-82.
39. Sobin LH, Fleming ID. Tnm classification of malignant tumors. Cancer 1997; 80: 1803-1804.
40. Lee SW, Ahn YY, Kim YS, Kang SB, Nam SW, Lee DS, Jeong HY, Kim JM. The immunohistochemical expression of stat3, bcl-xl, and mmp-2 proteins in colon adenoma and adenocarcinoma. Gut Liver 2012; 6: 45-51.
41. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, Wei D. Prognostic significance of bcl-xl gene expression in human colorectal cancer. Acta Histochem 2011; 113: 810-814.
42. Mallick S, Agarwal J, Kannan S, Pawar S, Kane S, Teni T. Bcl-xl protein: Predictor of complete tumor response in patients with oral cancer treated with curative radiotherapy. Head Neck 2013; 35: 1448-1453.
43. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. Santa Clara: Springer; 1997.
44. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567.
45. Yoshimine S, Kikuchi E, Kosaka T, Mikami S, Miyajima A, Okada Y, Oya M. Prognostic significance of bcl-xl expression and efficacy of bcl-xl targeting therapy in urothelial carcinoma. Br J Cancer 2013; 108: 2312-2320.
46. Xie X, Clausen O, De Angelis P, Boysen M. Bax expression has prognostic significance that is enhanced when combined with agnor counts in glottic carcinomas. Br J Cancer 1998; 78: 100.
47. Kruger NJ. The bradford method for protein quantitation. Methods Mol Biol 1994; 32: 9-15.
48. Jia L, Ma S, Hou X, Wang X, Qased ABL, Sun X, Liang N, Li H, Yi H, Kong D. The synergistic effects of traditional chinese herbs and radiotherapy for cancer treatment (review). Oncol Lett 2013; 5: 1439-1447.
49. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope 2002; 112: 616-625.
50. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
51. Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 1-11.
52. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-xl and bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85: 164-170.
53. Li LJ, Li Y, Wen YM, Liu H, Zhao HW. Clinical analysis of salivary gland tumor cases in west china in past 50 years. Oral Oncol 2008; 44: 187-192.
54. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Expression of bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathol 2010; 57: 304-316.
55. Mozzetti S, Ferrandina G, Marone M, D'Ingiullo F, Fruscella E, De Pasqua A, Mancuso S, Scambia G. Expression of bcl-2, bax-xl, and bcl-xs in endometrial and cervical tissues. Cancer Det Prev 1999; 24: 536-541.
56. Wang ZX, Yang JS, Pan X, Wang JR, Li J, Yin YM, De W. Functional and biological analysis of bcl-xl expression in human osteosarcoma. Bone 2010; 47: 445-454.
57. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Korobowicz E, Korszen-Pilecka I, Zdunek M. Estimation of prognostic value of bcl-xl gene expression in non-small cell lung cancer. Lung Cancer 2006; 51: 61-69.
58. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M. Expression of bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: Correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112: 638-644.
59. Gryko M, Pryczynicz A, Guzinska-Ustymowicz K, Kamocki Z, Zareba K, Kemona A, Kedra B. Immunohistochemical assessment of apoptosis-associated proteins: P53, bcl-xl, bax and bak in gastric cancer cells in correlation with clinical and pathomorphological factors. Adv Med Sci 2012; 57: 77-83.
60. Dodier P, Piché A. Bcl-xl is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol Oncol 2006; 100: 254-263.
61. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN. Egfr, p16, hpv titer, bcl-xl and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.